Unknown

Dataset Information

0

Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide.


ABSTRACT: We conducted a randomized clinical trial in 45 patients with resected AJCC stage IIB-IV melanoma to characterize cellular and molecular events at sites of immunization with incomplete Freund's adjuvant (IFA) alone, or a melanoma vaccine in IFA. At a primary vaccine site, all patients received a multi-peptide melanoma vaccine in IFA. At a replicate vaccine site, which was biopsied, group 1 received IFA only; group 2 received vaccine in IFA. Lymphocytes isolated from replicate vaccine site microenvironments (VSME) were compared to time-matched peripheral blood mononuclear cells (PBMC) in ELISpot and flow cytometry assays. Compared to PBMC, the VSME had fewer naïve and greater proportions of effector memory CD8(+) T cells (TCD8). The vast majority of TCD8 within the VSME were activated (CD69(+)), with a concentration of antigen-specific (tetramer(pos)) cells in the VSME, particularly in vaccine sites with peptide (group 2). CXCR3(+) lymphocytes were concentrated in the VSME of all patients, suggesting IFA-induced chemokine recruitment. TCD8 expression of retention integrins ?E?7 and ?1?1 was elevated in VSME, with the highest levels observed in antigen-specific cells in VSME containing peptide (group 2). TCD8 retained in the VSME of both groups were strikingly dysfunctional, with minimal IFN-? production in response to peptide stimulation and few tetramer(pos) cells producing IFN-?. These data suggest that vaccine-induced selective retention and dysfunction of antigen-specific TCD8 within VSME may represent a significant mechanism underlying transient immune responses and low clinical response rates to peptide vaccines administered in IFA.

SUBMITTER: Salerno EP 

PROVIDER: S-EPMC3813823 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide.

Salerno Elise P EP   Shea Sofia M SM   Olson Walter C WC   Petroni Gina R GR   Smolkin Mark E ME   McSkimming Chantel C   Chianese-Bullock Kimberly A KA   Slingluff Craig L CL  

Cancer immunology, immunotherapy : CII 20130509 7


We conducted a randomized clinical trial in 45 patients with resected AJCC stage IIB-IV melanoma to characterize cellular and molecular events at sites of immunization with incomplete Freund's adjuvant (IFA) alone, or a melanoma vaccine in IFA. At a primary vaccine site, all patients received a multi-peptide melanoma vaccine in IFA. At a replicate vaccine site, which was biopsied, group 1 received IFA only; group 2 received vaccine in IFA. Lymphocytes isolated from replicate vaccine site microen  ...[more]

Similar Datasets

| S-EPMC8378357 | biostudies-literature
| S-EPMC6598303 | biostudies-literature
| S-EPMC7213888 | biostudies-literature
| S-EPMC5723532 | biostudies-literature
| S-EPMC7752219 | biostudies-literature
| S-EPMC4002463 | biostudies-other
| S-EPMC7125112 | biostudies-literature
| S-EPMC5849214 | biostudies-literature
2018-12-31 | GSE111115 | GEO